Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindMaze Therapeutics HoldingXSWX:MMTX +3.33%4 Days Sales Outstanding is 581.61 as of Dec. 2025, which is at its 10-year median of 581.61. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 841 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 95.6% on this metric.
The historical rank and industry rank for MindMaze Therapeutics Holding's Days Sales Outstanding or its related term are showing as below:
XSWX:MMTX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 581.61 Med: 581.61 Max: 581.61
Current: 581.61
During the past 2 years, MindMaze Therapeutics Holding's highest Days Sales Outstanding was 581.61. The lowest was 581.61. And the median was 581.61.
XSWX:MMTX's Days Sales Outstanding is ranked worse than 95.6% of 841
companies
in the Biotechnology industry
Industry Median: 68.94
vs XSWX:MMTX: 581.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Days Sales Outstanding Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
Days Sales Outstanding
0.00
581.61
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
Days Sales Outstanding
0.00
581.61
XSWX:MMTX vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Days Sales Outstanding falls into.
MindMaze Therapeutics Holding Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 581.61 mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Days Sales Outstanding of 581.61 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on MindMaze Therapeutics Holding and its competitors. This is near median its historical median of 581.61. Over the past decade, MindMaze Therapeutics Holding's Days Sales Outstanding has ranged from 581.61 to 581.61. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #804 out of 841 companies in the Biotechnology industry, placing it in the top 95.6%.
Is MindMaze Therapeutics Holding's Days Sales Outstanding too high?
MindMaze Therapeutics Holding's current Days Sales Outstanding of 581.61 is near median its 10-year median of 581.61. Over the past 10 years, this metric has ranged from a low of 581.61 to a high of 581.61. The Biotechnology industry median Days Sales Outstanding is 68.94. MindMaze Therapeutics Holding's value of 581.61 is 743.6% above this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #804 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #804 out of 841 companies for Days Sales Outstanding. This places MindMaze Therapeutics Holding in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. MindMaze Therapeutics Holding's value of 581.61 is 743.6% above this benchmark. Historically, MindMaze Therapeutics Holding's own Days Sales Outstanding has ranged from 581.61 to 581.61 over the past decade. While the company's 10-year median is 581.61 vs. the industry median of 68.94, MindMaze Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current Days Sales Outstanding of 581.61 is 743.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current Days Sales Outstanding is 581.61, which is near median its own 10-year median of 581.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Days Sales Outstanding of 581.61. The current Days Sales Outstanding is 581.61, which is near median its 10-year median of 581.61 and 743.6% above the Biotechnology industry median of 68.94. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Days Sales Outstanding is 581.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
